Rampart Health is a clinical service-based, development-stage company whose mission is to discover, develop, and introduce innovative approaches for immunotherapy. Our R&D pipeline of new investigational treatments includes multiple target cancers, including prostate cancer, bladder cancer, renal cell cancer, melanoma, and pancreatic cancer.
Rampart Health consists of experienced medical professionals with decades of expertise in cancer therapeutics working together. Our goal is to exploit every cancer patient’s immune system to harness the abscopal effect hidden within.
Dr. David Bostwick MD, MBA
CEO & President
Dr. David G. Bostwick, MD, MBA is founder and Chief Executive Officer of Bostwick Laboratories (a division of Poplar Healthcare), Chief Medical Officer of Granger Genetics, and Chief Medical Officer of Rampart Health. He trained at the University of Maryland and Stanford University, and was formerly a Professor of Urology and Pathology at the Mayo Clinic from 1991 to 1999. Dr. Bostwick is internationally renowned, with 40 years of experience and interest in prostate cancer, bladder cancer and urologic diseases. He has previously held appointments at the National Cancer Institute, Stanford University, University of Chicago, University of Maryland, and Mayo Clinic. He has authored 17 books, more than 25 book chapters and more than 450 professional papers. His textbook, Urologic Surgical Pathology, (WB Saunders, 3rd Edition, 2014) is the best selling book in Uropathology. Dr. Bostwick published more papers with the keywords “prostate cancer” in the decade from 1990 to 2000 than any other investigator (independent MedLine review, 2001). He is also the most sought-after pathologist for second opinions in prostate pathology. Dr. Bostwick founded and served as the President of the International Society of Urological Pathology. He has presented more than 2000 lectures around the world, and served as Principal Investigator or Co-Investigator for more than 10 clinical trials Other former best-sellers are his books American Cancer Society’s Complete Guide to Prostate Cancer (American Cancer Society, 2005) and Essentials of Pathology, 4rd Edition (Springer 2017). His most quoted works include the first descriptions of the origin of prostate cancer (prostatic intraepithelial neoplasia) and the most important mimic of prostate cancer (atypical small acinar proliferation). He is currently pursuing novel approaches to immunotherapy for metastatic cancer.
Dr. Peter J. Littrup, MD
Chief Medical Officer
Dr. Peter Littrup is a globally-recognized scientist in medical imaging and intervention. He is a board-certified radiologist and clinically active breast imager who has conducted extensive research in the domains of cancer screening, ultrasound technology, biopsy guidance, and tumor ablation. He is renowned for expertise in application of cryosurgical treatment of cancer throughout the body. He joined Ascension Providence Rochester Hospital (Rochester Hills, MI) from Brown University where he was a full Professor in the Department of Diagnostic Imaging. His past experience includes serving as Director of the Ablation Program at Karmanos Cancer Institute and currently as a full Professor of Radiology and Oncology at Wayne State University. He has been developing a Tumor Ablation program at Ascension Providence Rochester Hospital. In 2020, he joined Rampart Health as its Chief Medical Officer.
Melanie Wilk, M.Sc.
Senior VP, Clinical Trials Development
Melanie Wilk has over fourteen years of experience in clinical trials research, regulations and management across both academic and industry setting. Prior to joining Rampart Health two years ago where she is currently the Senior Vice President, Clinical Trials Management, she was the Director of Clinical Trials for Bostwick Laboratories where she oversaw the execution of multi-site, large-scale clinical trials and research studies sponsored by pharmaceutical and biotech companies. She also supervised investigator-initiated studies sponsored by Bostwick laboratories. Over the course of her career she was successful in the management of more than 35 clinical trials (phase I-IV) in areas of pathology (cytopathology, dermatopathology, gastroenterology, genitourinary pathology, gynecologic pathology, hematopathology, molecular diagnostics and nephropathology).
Ms. Wilk has a Master of Science in Biology with a Specialty in Microbiology from Middle Tennessee State University. She also holds a Bachelor of Science in Biology, Concentration Pre-Med, Minor in Chemistry from East Tennessee State University. Ms. Wilk is an author and co-author of multiple scientific publications and presentations.